Clinical Evaluation of Standardized Bhringaraj (Eclipta alba) Extract Tablets in Hair Fall: A 24 Week Prospective Trial

Background: Hair fall is a frequent dermatological complaint with high prevalence and psychosocial impact. Conventional therapies often show variable efficacy and tolerability, prompting evaluation of botanicals such as Bhringaraj (Eclipta alba), traditionally described for hair health but rarely tested in structured clinical trials. Methods: A prospective, open‑label, pre–post-trial was conducted in adults aged 18–55 years with increased hair shedding. Participants received standardized oral Eclipta alba extract tablets for 24 weeks. Primary outcomes were hair shedding counts (60‑second comb test) and weekly diary totals, assessed at baseline, Week 12, and Week 24. Secondary outcome was Patient Global Impression of Change (PGIC). Safety was monitored through adverse events, vital signs, and hepatic function tests. Results: Fifty‑four participants were enrolled; 50 completed the study. Mean age was 34.6 years, with 58% female. Comb test counts decreased from 72.4 ± 18.6 hairs at baseline to 27.1 ± 11.8 at Week 24 (–62.5%, p < 0.0001). Weekly diary counts declined from 512.6 ± 104.2 to 205.4 ± 82.1 hairs (–59.9%, p < 0.0001). PGIC showed 84% reported improvement at Week 24. No serious adverse events occurred; mild gastrointestinal discomfort resolved spontaneously. Conclusion: Standardized Bhringaraj extract tablets significantly reduced hair shedding over 24 weeks, corroborated by patient‑reported outcomes and favorable safety, supporting further controlled trials to establish their role in hair fall management.